The main objective of this study is to evaluate the effectiveness and safety of SHR-A2102 for participants with advanced gynaecological cancer.
Participate in the study voluntarily, sign the informed consent form.
Recurrent or metastatic gynecological malignancies that had failed standard treatments.
At least one measurable lesion (RECIST version 1.1).
ECOG 0~ 1.
With untreated brain metastasis or concomitant meningeal metastasis and spinal cord compression.
Previous or contemporaneous malignancies, unless these malignancies reached complete remission at least 5 years prior before screening and did not require or are not expected to require other treatment during the study period. Such as Cutaneous squamous cell carcinoma, cervical carcinoma in situ etc.
Had previously received antibody drug conjugates containing topoisomerase I inhibitors.
Had undergone major surgery other than a diagnosis or biopsy within 28 days prior to the first administration; undergone minor traumatic surgery within 7 days prior to first administration.